258 related articles for article (PubMed ID: 25012137)
1. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Nanhwan MK; Ling S; Kodakandla M; Nylander S; Ye Y; Birnbaum Y
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2078-85. PubMed ID: 25012137
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
Ye Y; Birnbaum GD; Perez-Polo JR; Nanhwan MK; Nylander S; Birnbaum Y
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1805-14. PubMed ID: 26044583
[TBL] [Abstract][Full Text] [Related]
3. Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
Vilahur G; Gutiérrez M; Casani L; Varela L; Capdevila A; Pons-Lladó G; Carreras F; Carlsson L; Hidalgo A; Badimon L
Circulation; 2016 Nov; 134(22):1708-1719. PubMed ID: 27789556
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.
Birnbaum Y; Birnbaum GD; Birnbaum I; Nylander S; Ye Y
Cardiovasc Drugs Ther; 2016 Dec; 30(6):539-550. PubMed ID: 27830382
[TBL] [Abstract][Full Text] [Related]
5. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Birnbaum Y; Lin Y; Ye Y; Martinez JD; Huang MH; Lui CY; Perez-Polo JR; Uretsky BF
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2891-7. PubMed ID: 17277020
[TBL] [Abstract][Full Text] [Related]
6. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
7. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin.
Ye Y; Long B; Qian J; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):391-9. PubMed ID: 20640495
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
9. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
10. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
11. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia-reperfused isolated mouse heart.
Urmaliya VB; Pouton CW; Ledent C; Short JL; White PJ
J Cardiovasc Pharmacol; 2010 Oct; 56(4):379-88. PubMed ID: 20930592
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
Ye Y; Lin Y; Manickavasagam S; Perez-Polo JR; Tieu BC; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2436-46. PubMed ID: 18931027
[TBL] [Abstract][Full Text] [Related]
13. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
15. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion.
Birnbaum Y; Tran D; Chen H; Nylander S; Sampaio LC; Ye Y
Cell Physiol Biochem; 2019; 53(6):961-981. PubMed ID: 31820856
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Mahaffey KW; Wojdyla DM; Carroll K; Becker RC; Storey RF; Angiolillo DJ; Held C; Cannon CP; James S; Pieper KS; Horrow J; Harrington RA; Wallentin L;
Circulation; 2011 Aug; 124(5):544-54. PubMed ID: 21709065
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
19. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
